Californians for Stem Cell Research Treatments and Cures (EIN 843660007) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2019

Legal Domicile

Principal Officer

Robert Klein III

Phone

4153896800

Tax Period

2021-01-01 to 2021-12-31

Californians for Stem Cell Research Treatments and Cures, founded in 2019, is a small nonprofit that reported $494K in total revenue in fiscal year 2021. Revenue fell 95% from the prior year — a significant decline worth monitoring. The organization ran a surplus of $356K, a strong 72% operating margin.

Mission

To support the California Stem Cell Research, Treatments and Cures Initiative of 2020 on the November 2020 statewide ballot.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2021)

Revenue Breakdown

Contributions & Grants $494,470

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $494,470

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $96,490

Other Expenses $138,955

TOTAL EXPENSES $138,955

Year-over-Year Comparison

	2021	2020	Change
Revenue	$494,470	$10,237,827	-1.0%
Expenses	$138,955	$10,232,762	-1.0%
Net Income	$355,515	$5,065	+69.2%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Robert N Klein II	President/Dir.	1.00	Officer Director	$0	$0	$0
Robert Klein III	Treasurer/Dir.	1.00	Officer Director	$0	$0	$0
Don C Reed	Secretary/Dir.	1.00	Officer Director	$0	$0	$0
Bernie Siegel	Director	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2021	$494,470	$138,955	$3,853	$355,515
2020	$10,237,827	$10,232,762	$5,065	$5,065

Californians for Stem Cell Research Treatments and Cures